广东鹍鹏肽灵生物科技

Guangdong Kunpeng Tailing Biotechnology is a biopharmaceutical company specializing in the development of oral peptide therapeutics. The company leverages a proprietary oral delivery platform designed to overcome the biological barriers of the gastrointestinal tract, which typically prevent the effective absorption of peptide-based drugs. Its primary research focus is on metabolic diseases, particularly the development of oral formulations for GLP-1 receptor agonists and insulin. By converting injectable treatments into oral dosage forms, Kunpeng Tailing aims to significantly improve patient compliance and quality of life for those with chronic conditions like diabetes and obesity. The company is strategically located in the Guangzhou Bio-Island, a major hub for biotechnology innovation in China.